Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin, Chief Commercial Officer of Aldeyra, will present at Oppenheimer & Co.’s 30^th Annual Healthcare Conference in New York City. The presentation is scheduled to begin at 10:55 a.m. (ET) Tuesday, March 17, 2020.

A live webcast of the presentation can be accessed on the “Investors & Media” section of the Aldeyra website, https://ir.aldeyra.com/. An audio replay will be available following the live presentation and will be archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005212/en/